- Home
- FATE vs CUE Comparison
FATE vs CUE Comparison
Compare FATE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | CUE |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 124.5M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FATE | CUE |
|---|---|---|
| Price | $1.99 | $26.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $4.10 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 4.3M | 68.0K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.88 | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | $6,646,000.00 | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.91 | $0.17 |
| 52 Week High | $2.88 | $41.42 |
Technical Indicators
Market Signals| Indicator | FATE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 54.71 |
| Support Level | $1.00 | $0.30 |
| Resistance Level | $2.88 | $32.60 |
| Average True Range (ATR) | 0.21 | 3.77 |
| MACD | -0.06 | -0.65 |
| Stochastic Oscillator | 16.04 | 48.31 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.